Uncategorized

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the market for cancer, influenza and more.

Launched in 2020 to more quickly bring to market an effective medicine for amyotrophic lateral sclerosis, the HEALEY Platform Trial has generated disappointing results for many but also continuing programs from Clene and Prilenia.

Just over 5% of companies selling AI to health systems have matured beyond seed and early-stage funding rounds, according to an analysis by Flare Capital Partners.

Still, plans are expected to rake in $11.8 billion in bonuses, with half of that tranche going to just two insurers: UnitedHealthcare and Humana.

Inflammatix has now raised over $200 million in private capital, in addition to more than $50 million in grants and contracts.

Silk Road Medical said in a securities filing that the antitrust waiting period expired Thursday evening, opening the door to complete the $1.26 billion deal.

Bicara Therapeutics, Zenas BioPharma and MBX Biosciences are seeking a combined $700 million-plus in IPO filings this week.

During an investor day Thursday, Moderna’s R&D chief Stephen Hoge detailed plans for the famed biotech to trim R&D spending in preparation for the launch of up to 10 new products.

It’s time for Congress to step up and fund America’s supply chain independence from Chinese companies by bolstering our domestic manufacturing capabilities.

Oncternal Therapeutics will lay off about 10 workers as it explores “strategic alternatives” that could include asset sales or an M&A.